Receive our newsletter – data, insights and analysis delivered to you
June 2, 2009

MedImmune Lands Swine Flu Vaccine contract from US Health Dept

MedImmune has been awarded a contract from the US Department of Health and Human Services (HHS) to manufacture an influenza vaccine for the novel influenza A (H1N1) strain. The monovalent (single-strain) live attenuated influenza drug will be used to vaccinate priority populations ident

By cms admin

MedImmune has been awarded a contract from the US Department of Health and Human Services (HHS) to manufacture an influenza vaccine for the novel influenza A (H1N1) strain.

The monovalent (single-strain) live attenuated influenza drug will be used to vaccinate priority populations identified by HHS in its National Strategy for Pandemic Influenza.

An initial order of $90m has been placed for the vaccine.

MedImmune scientists have identified several promising vaccine candidates against the novel influenza A (H1N1) strain. The company is now evaluating their growth properties and antigenicity for mass production.

MedImmune executive vice president of operations Ben Machielse said that the company was pleased to be able to contribute to combating this unpredictable public health threat.

“We are confident that our vaccine technology has several attributes that may be useful in protecting people with limited exposure to influenza against the novel influenza A (H1N1) strain,” said Machielse.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

MedImmune’s live attenuated influenza vaccine is different from the injectable influenza drug in that it is a gentle mist sprayed into the nose, where the influenza virus usually enters the body.

The dose contains live virus strains that are weakened so as not to cause the flu but prompt the body to mount an immune response after the first dose.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU